TY - JOUR
T1 - Maintenance azithromycin therapy for bronchiolitis obliterans syndrome
T2 - Results of a pilot study
AU - Gerhardt, Susan G.
AU - McDyer, John F.
AU - Girgis, Reda E.
AU - Conte, John
AU - Yang, Stephen C.
AU - Orens, Jonathan B.
PY - 2003/7/1
Y1 - 2003/7/1
N2 - Bronchiolitis obliterans syndrome remains the leading cause of morbidity and mortality in the pulmonary transplant population. Previous studies show that macrolide antibiotics may be efficacious in the treatment of panbronchiolitis and cystic fibrosis. In the latter, azithromycin decreases the number of respiratory exacerbations, improves FEV1, and improves quality of life. We hypothesized that oral azithromycin therapy may improve lung function in patients with bronchiolitis obliterans syndrome. To test this hypothesis, we conducted an open-label pilot trial using maintenance azithromycin therapy in six lung transplant recipients (250 mg orally three times per week for a mean of 13.7 weeks). In this study, five of these six individuals demonstrated significant improvement in pulmonary function, as assessed by FEV1, as compared with their baseline values at the start of azithromycin therapy. The mean increase in the percentage of predicted FEV1 values in these individuals was 17.1% (p ≤ 0.05). In addition, the absolute FEV1 increased by 0.50 L (range -0.18 to 1.36 L). These data suggest a potential role for maintenance macrolide therapy in the treatment of bronchiolitis obliterans syndrome in lung transplant recipients.
AB - Bronchiolitis obliterans syndrome remains the leading cause of morbidity and mortality in the pulmonary transplant population. Previous studies show that macrolide antibiotics may be efficacious in the treatment of panbronchiolitis and cystic fibrosis. In the latter, azithromycin decreases the number of respiratory exacerbations, improves FEV1, and improves quality of life. We hypothesized that oral azithromycin therapy may improve lung function in patients with bronchiolitis obliterans syndrome. To test this hypothesis, we conducted an open-label pilot trial using maintenance azithromycin therapy in six lung transplant recipients (250 mg orally three times per week for a mean of 13.7 weeks). In this study, five of these six individuals demonstrated significant improvement in pulmonary function, as assessed by FEV1, as compared with their baseline values at the start of azithromycin therapy. The mean increase in the percentage of predicted FEV1 values in these individuals was 17.1% (p ≤ 0.05). In addition, the absolute FEV1 increased by 0.50 L (range -0.18 to 1.36 L). These data suggest a potential role for maintenance macrolide therapy in the treatment of bronchiolitis obliterans syndrome in lung transplant recipients.
UR - http://www.scopus.com/inward/record.url?scp=0041803253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0041803253&partnerID=8YFLogxK
U2 - 10.1164/rccm.200212-1424BC
DO - 10.1164/rccm.200212-1424BC
M3 - Article
C2 - 12672648
AN - SCOPUS:0041803253
SN - 1073-449X
VL - 168
SP - 121
EP - 125
JO - American Review of Respiratory Disease
JF - American Review of Respiratory Disease
IS - 1
ER -